Rallybio publishes promising results with technology aquired from Prophylix Pharma
American biotech company Rallybio publishes proof-of-concept data from animal studies with technology aquired from Tromsø-based Prophylix Pharma
The American biotech company Rallybio (NASDAQ:RLYB) yesterday published data from animal studies confirming potential prophylactic potential of a hyperimmune-based concept for prevention of the rare condition FNAIT i newborns. The concept is based on research from UNN/UiT and further developed by Sarsia portfolio company Prophylix Pharma